Atlantic Family Wealth LLC purchased a new position in shares of Sanofi (NASDAQ:SNY – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,431 shares of the company’s stock, valued at approximately $262,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Abel Hall LLC increased its stake in Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after acquiring an additional 194 shares during the last quarter. PDS Planning Inc lifted its holdings in shares of Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after purchasing an additional 200 shares during the last quarter. Financial Advocates Investment Management lifted its holdings in shares of Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after purchasing an additional 206 shares during the last quarter. Angeles Investment Advisors LLC lifted its holdings in shares of Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after purchasing an additional 210 shares during the last quarter. Finally, Keudell Morrison Wealth Management raised its stake in Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after acquiring an additional 217 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.
Sanofi Price Performance
NASDAQ SNY opened at $54.46 on Friday. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a market capitalization of $138.21 billion, a PE ratio of 21.87, a P/E/G ratio of 1.01 and a beta of 0.57. The stock has a 50-day simple moving average of $50.95 and a 200 day simple moving average of $52.53.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on SNY. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi presently has an average rating of “Buy” and a consensus price target of $60.00.
Check Out Our Latest Analysis on SNY
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
- Five stocks we like better than Sanofi
- The Role Economic Reports Play in a Successful Investment Strategy
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What is Insider Trading? What You Can Learn from Insider Trading
- DuPont’s Electronics Spinoff: The Start of Something Big
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.